Advertisement

Analytical and Bioanalytical Chemistry

, Volume 410, Issue 29, pp 7565–7573 | Cite as

Ultrafiltration binding analyses of glycated albumin with a 3D-printed syringe attachment

  • Andre D. Castiaux
  • Cody W. Pinger
  • Dana M. SpenceEmail author
Paper in Forefront
Part of the following topical collections:
  1. ABC Highlights: authored by Rising Stars and Top Experts

Abstract

Protein-ligand binding assays facilitate the understanding of biomolecular interactions. Classical equilibrium dialysis methods are often used for accurate determination of binding properties. While accurate, the long equilibration times associated with the technique (> 6 h) hinder throughput. Here, in an attempt to gather high-accuracy results while reducing total analysis time, a low pressure ultrafiltration method that relies on a simple membrane-containing syringe attachment was developed. A minimal portion (1–2%) of the solution containing the binding analytes of interest is driven through the membrane pores and collected for analysis. Specifically, the device was used to investigate the binding affinity between Zn2+ and either normal human serum albumin (nHSA) or a commercially purchased glycated human serum albumin (gHSA). Both of these ligand/protein-binding systems have implications in type 1 diabetes. The device was then used to investigate the binding between the various albumin types and C-peptide, the 31 amino acid peptide that is co-secreted with insulin from pancreatic β cells. Results for nHSA/Zn2+ binding obtained using the ultrafiltration method (Kd = 5.77 ± 0.19 × 10−7 M) were statistically equivalent with results reported using other methods. Importantly, the amount of Zn2+ bound to the nHSA was significantly different from the gHSA (97 ± 2% protein bound vs. 91 ± 3%, respectively p < 0.05). The binding affinity of C-peptide to nHSA (Kd = 2.4 ± 0.3 × 10−6 M) agreed with values reported in the literature using standard techniques. Unlike Zn2+ binding, the binding of C-peptide to nHSA was statistically equal to its binding to gHSA (77.7 ± 6.2 and 78.8 ± 7.4%, respectively), suggesting that C-peptide replacement therapy in people with T1D may be strongly dependent upon the characteristics of Zn2+ binding to human serum albumin.

Graphical abstract

Keywords

Metals/heavy metals Microfluidics/microfabrication Separations/instrumentation Bioanalytical methods Binding affinity constants 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

216_2018_1373_MOESM1_ESM.pdf (453 kb)
ESM 1 (PDF 452 kb)

References

  1. 1.
    International Diabetes Federation Diabetes Atlas. International Diabetes Federation; 2017.Google Scholar
  2. 2.
    Williams SB, Cusco JA, Roddy M-A, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27(3):567–74.CrossRefGoogle Scholar
  3. 3.
    McVeigh G, Brennan G, Johnston G, McDermott B, McGrath L, Henry W, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(8):771–6.PubMedGoogle Scholar
  4. 4.
    Dugan J, Pfotenhauer K, Young C, Shubrook JH. Diabetes microvascular complications. Primary Care Reports. 2017;23(5).Google Scholar
  5. 5.
    Banting F, Campbell W, Fletcher A. Further clinical experience with insulin (pancreatic extracts) in the treatment of diabetes mellitus. Br Med J. 1923;1(3236):8.CrossRefGoogle Scholar
  6. 6.
    Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3(4):267.CrossRefGoogle Scholar
  7. 7.
    Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89(1):3–9.CrossRefGoogle Scholar
  8. 8.
    Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, et al. Molecular biology of mammalian glucose transporters. Diabetes Care. 1990;13(3):198–208.CrossRefGoogle Scholar
  9. 9.
    Medawala W, McCahill P, Giebink A, Meyer J, Ku C-J, Spence DM. A molecular level understanding of zinc activation of C-peptide and its effects on cellular communication in the bloodstream. Rev Diabet Stud. 2009;6(3):148.CrossRefGoogle Scholar
  10. 10.
    Sima AA. Diabetes & C-peptide: scientific and clinical aspects. Springer Science & Business Media; 2011.Google Scholar
  11. 11.
    Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science. 1967;157(3789):697–700.CrossRefGoogle Scholar
  12. 12.
    Rubenstein AH, Clark JL, Melani F, Steiner DF. Secretion of proinsulin C-peptide by pancreatic β cells and its circulation in blood. Nature. 1969;224(5220):697–9.CrossRefGoogle Scholar
  13. 13.
    Cotter MA, Cameron NE. C-peptide effects on nerve conduction and blood flow in streptozotocin-induced diabetic rats: modulation by nitric oxide synthase inhibition. Diabetes. 2001;50:A184.Google Scholar
  14. 14.
    Sima AAF, Zhang W, Sugimoto K, Henry D, Li Z, Wahren J, et al. C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia. 2001;44(7):889–97.CrossRefGoogle Scholar
  15. 15.
    Liu Y, Chen C, Summers S, Medawala W, Spence DM. C-peptide and zinc delivery to erythrocytes requires the presence of albumin: implications in diabetes explored with a 3D-printed fluidic device. Integr Biol. 2015;7(5):534–43.CrossRefGoogle Scholar
  16. 16.
    Pinger CW, Entwistle K, Bell T, Liu Y, Spence D. C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment? Mol BioSyst. 2017;13(8):1432–7.CrossRefGoogle Scholar
  17. 17.
    Meyer JA, Froelich JM, Reid GE, Karunarathne WK, Spence DM. Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter. Diabetologia. 2008;51(1):175–82.CrossRefGoogle Scholar
  18. 18.
    Wahren J, Foyt H, Daniels M, Arezzo JC. Long-acting C-peptide and neuropathy in type 1 diabetes: a 12-month clinical trial. Diabetes Care. 2016;39(4):596–602.CrossRefGoogle Scholar
  19. 19.
    Pinger CW, Heller AA, Spence DM. A printed equilibrium dialysis device with integrated membranes for improved binding affinity measurements. Anal Chem. 2017;89(14):7302–6.CrossRefGoogle Scholar
  20. 20.
    Melten JW, Wittebrood AJ, Willems HJ, Faber GH, Wemer J, Faber DB. Comparison of equilibrium dialysis, ultrafiltration, and gel permeation chromatography for the determination of free fractions of phenobarbital and phenytoin. J Pharm Sci. 1985;74:692–4.CrossRefGoogle Scholar
  21. 21.
    Barnaby OS, Cerny RL, Clarke W, Hage DS. Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-labeling and MALDI–TOF MS. Clin Chim Acta. 2011;412(17–18):1606–15.CrossRefGoogle Scholar
  22. 22.
    Anguizola J, Matsuda R, Barnaby OS, Hoy KS, Wa C, DeBolt E, et al. Review: glycation of human serum albumin. Clin Chim Acta. 2013;425:64–76.CrossRefGoogle Scholar
  23. 23.
    Hage DS. Analysis of biological interactions by affinity chromatography: clinical and pharmaceutical applications. Clin Chem. 2017;clinchem. 2016.262253.Google Scholar
  24. 24.
    Barnaby OS, Cerny RL, Clarke W, Hage DS. Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta. 2011;412(3–4):277–85.CrossRefGoogle Scholar
  25. 25.
    Matsuda R, Anguizola J, Joseph K, Hage DS. High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin. Anal Bioanal Chem. 2011;401(9):2811.CrossRefGoogle Scholar
  26. 26.
    Baraka-Vidot J, Guerin-Dubourg A, Bourdon E, Rondeau P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie. 2012;94(9):1960–7.CrossRefGoogle Scholar
  27. 27.
    Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011;93(4):645–58.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Andre D. Castiaux
    • 1
    • 2
  • Cody W. Pinger
    • 1
    • 2
  • Dana M. Spence
    • 2
    • 3
    Email author
  1. 1.Department of ChemistryMichigan State UniversityEast LansingUSA
  2. 2.Michigan State UniversityInstitute for Quantitative Health Science & EngineeringEast LansingUSA
  3. 3.Department of Biomedical EngineeringMichigan State UniversityEast LansingUSA

Personalised recommendations